| Studientitel |
Status |
Seit |
Medikation |
| Incyte - A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations |
Aktiv |
17.01.2018 |
Tyrosine Kinase Inhibitor INCB054828 |
| WO29636 - A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION |
Aktiv |
Rekrutierung abgeschlossen |
Atezolizumab vs. Observation |
| GO35590 A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY |
In Planung |
|
Atezolizumab +/- MOXR0916 |
| POTOMAC: Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as Combination Therapy versus BCG alone in High Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients |
In Planung |
|
Durvalumab and BCG vs BCG alone |
| Ansprechpartner |
|
|
|
| OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: Tel.: 030-450 515288, Fax: 030-450 515927 |
|
|
|
